Clinical management of dilated cardiomyopathy: Current knowledge and future perspectives

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 2, 2016, Pages 137-140

  Merlo, Marco ^a   Cannatá, Antonio ^a   Vitagliano, Alice ^a   Zambon, Elena ^a   Lardieri, Gerardina ^a   Sinagra, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Dilated cardiomyopathy; LCZ 696; Left ventricular reverse remodeling; Phosphodiesterase inhibitors

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; MILRINONE; PHOSPHODIESTERASE; SACUBITRIL PLUS VALSARTAN;

CARDIAC RESYNCHRONIZATION THERAPY; CELL THERAPY; CONGESTIVE CARDIOMYOPATHY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART FUNCTION; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR REVERSE REMODELING; REVIEW; CARDIOMYOPATHY, DILATED; HEART VENTRICLE; PATHOPHYSIOLOGY; PROGNOSIS;

CARDIOMYOPATHY, DILATED; HEART VENTRICLES; HUMANS; PROGNOSIS; VENTRICULAR REMODELING;

EID: 84957434181     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2016.1125292     Document Type: Review

References (25)

1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29: 270-276.
2. Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014; 16: 317-324.
3. Merlo M, Sinagra G, Carniel E, et al. Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy. Clin Transl Sci. 2013; 6: 424-428.
4. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10: 531-547.
5. Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. Glob Heart. 2013; 8: 355-382.
6. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113: 1807-1816.
7. Moretti M, Merlo M, Barbati G, et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail. 2010; 12: 922-927.
8. Aleksova A, Barbati G, Merlo M, et al. Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: data from the Trieste Cardiomyopathies Registry. Heart Lung. 2011; 40: 454-461.
9. Lapu-Bula R, Robert A, De Kock M, et al. Risk stratification in patients with dilated cardiomyopathy: contribution of Doppler-derived left ventricular filling. Am J Cardiol. 1998; 82: 779-785.
10. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013; 34: 1404-1413.
11. Aleksova A, Carriere C, Zecchin M, et al. New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace. 2014; 16: 1450-1459.
12. Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011; 57: 1468-1476.
13. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009; 324: 98-102.
14. Kyriakides ZS, Manolis AG, Kolettis TM. The effects of ventricular asynchrony on myocardial perfusion. Int J Cardiol. 2007; 119: 3-9.
15. Harmon WG, Sleeper LA, Cuniberti L, et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol. 2009; 104: 281-286.
16. Zecchin M, Merlo M, Pivetta A, et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with SCD-HeFT criteria?. Am J Cardiol. 2012; 109: 729-735.
17. Itoh M, Shinke T, Yoshida A, et al. Reduction in coronary microvascular resistance through cardiac resynchronization and its impact on chronic reverse remodelling of left ventricle in patients with non-ischaemic cardiomyopathy. Europace. 2015;17:1407-1414.
18. Stolfo D, Tonet E, Barbati G, et al. Acute hemodynamic response to cardiac resynchronization in dilated cardiomyopathy: effect on late mitral regurgitation. Pacing Clin Electrophysiol. 2015;38:1287-1296.
19. Deng XU, Xia KE, Chen PO, et al. Reversion of left ventricle remodeling in spontaneously hypertensive rats by valsartan is associated with the inhibition of caspase-3,-8 and-9 activities. Biomed Rep. 2015; 3: 533-536.
20. Tseliou E, Reich H, De Couto G, et al. Cardiospheres reverse adverse remodeling in chronic rat myocardial infarction: roles of soluble endoglin and Tgf-beta signaling. Basic Res Cardiol. 2014; 109: 443.
21. Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc. 2015; 4: e001504.
22. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004.
23. Nakano SJ, Miyamoto SD, Movsesian M, et al. Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail. 2015; 8: 57-63.
24. Kelkar AA, Butler J, Schelbert EB, et al. Mechanisms contributing to the progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol. 2015; 66: 2038-2047.
25. Woitek F, Zentilin L, Hoffman NE, et al. Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy. J Am Coll Cardiol. 2015; 66: 139-153.